SOPHiA GENETICS CFO discloses initial share holdings

SOPHiA GENETICS SA Chief Financial Officer George Cardoza filed an initial ownership report showing his equity position in the company.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Financial Officer George Cardoza filed an initial ownership report showing his equity position in the company. He holds 185,632 Ordinary Shares directly. He also holds share options over 183,333 Ordinary Shares at an exercise price of $3.4000 per share, expiring on December 18, 2034, and separate share options over 187,500 Ordinary Shares at an exercise price of $3.2900 per share, expiring on April 2, 2035. Footnotes state that 70,826 additional Ordinary Shares are issuable upon settlement of restricted stock units, vesting over time subject to his continued service.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider CARDOZA GEORGE

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 370,833 contracts (Direct); Ordinary Shares — 185,632 shares (Direct)

Footnotes (3)

1. F1. Includes 70,826 ordinary shares issuable upon settlement of two restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 28,388 ordinary shares from a December 18, 2024 grant vesting in equal quarterly installments through December 18, 2028; and (ii) 42,438 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
2. F2. The share option vests and becomes exercisable as to 25% of the ordinary shares on December 18, 2025, and then in equal monthly installments through December 18, 2028.
3. F3. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does George Cardoza’s Form 3 for SOPHiA GENETICS SA (SOPH) show?

The Form 3 reports George Cardoza’s initial ownership in SOPHiA GENETICS SA as Chief Financial Officer. It discloses his directly held Ordinary Shares, outstanding share options over additional Ordinary Shares, and restricted stock units that may convert into shares as vesting conditions are met.

How many SOPHiA GENETICS Ordinary Shares does George Cardoza directly own?

George Cardoza directly owns 185,632 Ordinary Shares of SOPHiA GENETICS SA. This figure reflects only his current share holdings, separate from any share options or restricted stock units that may increase his ownership if they vest or are exercised in the future.

What share options over SOPHiA GENETICS SA stock does George Cardoza hold?

He holds options over 183,333 Ordinary Shares at $3.4000 per share expiring on December 18, 2034, and options over 187,500 Ordinary Shares at $3.2900 per share expiring on April 2, 2035, all relating to SOPHiA GENETICS SA Ordinary Shares.

How many SOPHiA GENETICS SA shares are tied to George Cardoza’s RSUs?

Footnotes state that 70,826 Ordinary Shares are issuable upon settlement of two restricted stock unit grants. Each RSU represents a contingent right to one share, vesting over several years based on George Cardoza’s continued service with SOPHiA GENETICS SA.

How do George Cardoza’s SOPHiA GENETICS SA share options vest?

One option grant vests 25% on December 18, 2025, then in equal monthly installments through December 18, 2028. Another vests 50% on April 2, 2026, with the remainder vesting in equal monthly installments through April 2, 2027, subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 09:46 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

CARDOZA GEORGE

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	185,632(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(2)	12/18/2034	Ordinary Shares	183,333	$3.4	D
Share Option (Right to Buy)	(3)	04/02/2035	Ordinary Shares	187,500	$3.29	D

Explanation of Responses:

1. Includes 70,826 ordinary shares issuable upon settlement of two restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 28,388 ordinary shares from a December 18, 2024 grant vesting in equal quarterly installments through December 18, 2028; and (ii) 42,438 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.

2. The share option vests and becomes exercisable as to 25% of the ordinary shares on December 18, 2025, and then in equal monthly installments through December 18, 2028.

3. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney

	/s/ Elimara Brunetto as Attorney-in-Fact for George Cardoza	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)